Improving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol

[1]  T. Elías-Hernández,et al.  Real-life experience of inhaled iloprost for patients with pulmonary arterial hypertension: Insights from the Spanish REHAP registry. , 2019, International journal of cardiology.

[2]  S. Söderberg,et al.  A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension , 2018, European heart journal.

[3]  S. Rosenkranz,et al.  Long-term safety and outcome of intravenous treprostinil via an implanted pump in pulmonary hypertension. , 2018, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[4]  N. Galiè,et al.  Pulmonary Arterial Hypertension: Combination Therapy in Practice , 2018, American Journal of Cardiovascular Drugs.

[5]  A. Torbicki,et al.  Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. , 2018, Journal of the American College of Cardiology.

[6]  S. Rosenkranz,et al.  Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model , 2017, European Respiratory Journal.

[7]  M. Humbert,et al.  Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension , 2017, European Respiratory Journal.

[8]  K. Fukuda,et al.  Survival of Japanese Patients With Idiopathic/Heritable Pulmonary Arterial Hypertension. , 2017, The American journal of cardiology.

[9]  O. Sitbon,et al.  Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience , 2017, European Respiratory Review.

[10]  A. Ogawa,et al.  Rapid and high-dose titration of epoprostenol improves pulmonary hemodynamics and clinical outcomes in patients with idiopathic and heritable pulmonary arterial hypertension. , 2016, Journal of cardiology.

[11]  J. Barberà,et al.  Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. , 2016, The Lancet. Respiratory medicine.

[12]  M. Humbert,et al.  Initial dual oral combination therapy in pulmonary arterial hypertension , 2016, European Respiratory Journal.

[13]  R. Benza,et al.  Five-Year outcomes of patients enrolled in the REVEAL Registry. , 2015, Chest.

[14]  Simon Gibbs,et al.  2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension , 2015, European Respiratory Journal.

[15]  J. Barberà,et al.  Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. , 2015, The New England journal of medicine.

[16]  A. Ogawa,et al.  Long-term patient survival with idiopathic/heritable pulmonary arterial hypertension treated at a single center in Japan. , 2014, Life sciences.

[17]  M. Mcgoon,et al.  Characterization of First-Time Hospitalizations in Patients With Newly Diagnosed Pulmonary Arterial Hypertension in the REVEAL Registry , 2014, Chest.

[18]  M. Humbert,et al.  Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry. , 2014, International journal of cardiology.

[19]  Angelo Branzi,et al.  Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. , 2014, European heart journal.

[20]  M. Humbert,et al.  Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study , 2014, European Respiratory Journal.

[21]  H. Ghofrani,et al.  Selexipag for the Treatment of Pulmonary Arterial Hypertension. , 2014, The New England journal of medicine.

[22]  R. Benza,et al.  Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis. , 2013, Chest.

[23]  Dave P. Miller,et al.  Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[24]  M. Kingman,et al.  Safety recommendations for administering intravenous prostacyclins in the hospital. , 2013, Critical care nurse.

[25]  Z. Jing,et al.  Macitentan and morbidity and mortality in pulmonary arterial hypertension. , 2013, The New England journal of medicine.

[26]  M. Humbert,et al.  Riociguat for the treatment of pulmonary arterial hypertension. , 2013, The New England journal of medicine.

[27]  R. Barst,et al.  Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry. , 2013, Chest.

[28]  R. Benza,et al.  An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. , 2012, Chest.

[29]  M. Humbert,et al.  Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[30]  T. Welte,et al.  The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension , 2011, European Respiratory Journal.

[31]  Sally A. Arif,et al.  Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension. , 2011, Clinical therapeutics.

[32]  A. Ogawa,et al.  Marked hemodynamic improvements by high-dose epoprostenol therapy in patients with idiopathic pulmonary arterial hypertension. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[33]  MarcHumbert,et al.  Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era , 2010 .

[34]  A. Manes,et al.  Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses , 2010, European heart journal.

[35]  M. Humbert,et al.  Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era , 2010, Circulation.

[36]  L. Shapiro,et al.  Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[37]  F. Torres,et al.  Prostacyclin administration errors in pulmonary arterial hypertension patients admitted to hospitals in the United States: a national survey. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[38]  G. Simonneau,et al.  The use of combination therapy in pulmonary arterial hypertension: new developments , 2009, European Respiratory Review.

[39]  R. Benza,et al.  Guidelines for the prevention of central venous catheter‐related blood stream infections with prostanoid therapy for pulmonary arterial hypertension , 2008, International journal of clinical practice. Supplement.

[40]  G. Simonneau,et al.  Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial , 2008, The Lancet.

[41]  B. Wiens,et al.  Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 , 2008, Circulation.

[42]  T. Fleming,et al.  Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.

[43]  A. Negassa,et al.  Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. , 2005, European heart journal.

[44]  R. Barst,et al.  Survival with first-line bosentan in patients with primary pulmonary hypertension , 2005, European Respiratory Journal.

[45]  M. Humbert,et al.  Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 , 2004, European Respiratory Journal.

[46]  A. Shillington,et al.  Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy , 2002, Circulation.

[47]  Gilles Garcia,et al.  Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. , 2002, Journal of the American College of Cardiology.

[48]  R. Barst,et al.  Bosentan therapy for pulmonary arterial hypertension. , 2002, The New England journal of medicine.

[49]  S. Rich,et al.  Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.

[50]  D. Badesch,et al.  Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study , 2001, The Lancet.

[51]  Stuart Rich,et al.  Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.

[52]  B. Brundage,et al.  Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. , 1997, Journal of the American College of Cardiology.

[53]  B. Groves,et al.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.

[54]  E H Bergofsky,et al.  Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .

[55]  J. H. Diehl,et al.  Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol): Results of a Randomized Trial , 1990 .

[56]  B. Groves,et al.  Prostacyclin‐induced Acute Pulmonary Vasodilation in Primary Pulmonary Hypertension , 1982, Circulation.